Skip navigation

The European Commission has issued conditional marketing authorisation for the Moderna coronavirus vaccine

Conditional marketing authorisation for a second coronavirus vaccine in Europe has already been issued by the European Commission.

According to Ursula von der Leyen, president of the European Commission, Europe now has more vaccines available in its fight to enable everyone in its member states to protect themselves from the virus.

Stella Kyriakides, European Commissioner for Health and Food Safety, claimed that the European Commission had been holding negotiations on forming the widest vaccine portfolio in the world for its member states. ‘Today we are authorising the use of the Moderna vaccine, a second safe and efficient vaccine which will produce 460 million doses within the European Union, along with the BioNTech-Pfizer vaccine. There will certainly be more vaccines becoming available. We will not cease in our efforts until vaccines have been made available to everyone across the entire European Union.’

The decision by the European Commission is based on an assessment by the committee for Medicinal Products for Human Use, which is part of the European Medicines Agency. That assessment was published today.

All EU member state representatives who are part of the Committee for Medicinal Products for Human Use within the European Medicines Agency reached a consensus that the information which had been submitted by the manufacturer was sufficient to allow them to authorise the marketing of what they agreed was a sufficiently safe, efficient, and high-quality coronavirus vaccine.

After being granted marketing authorisation, the manufacturer’s vaccine – which is known in full as COVID-19 Vaccine Moderna – may be supplied to all European Union member states.

Source: State Agency of Medicines

www.ravimiamet.ee/euroopa-komisjon-andis-moderna-koroonavaktsiinile-tingimustega-m%C3%BC%C3%BCgiloa

News, COVID-19, Moderna
Scroll to top